Sort by 'comments'
Myeloma 2015. Year in Review with the MMRF
2015 saw a lot of action in the Myeloma world. Four new drugs were approved by the FDA increasing treatment options and allowing new combination regimens; promising immunotherapy research results will see these being used in clinical practice and 1000…
How Will New Imaging Techniques and Genomic Tests Help In Diagnosis and Management of Prostate Cancer.
Recent advances in prostate cancer has led to the discovery of many new imaging and genomic tests. Information on the new tests and techniques can help patients in making informed decisions regarding their prostate cancer diagnosis, treatments and management options…
What you need to know about the ICER report and its implication on insurance coverage and treatment options for myeloma patients.
Cancer drugs cost more than $100,000 per year and continue to increase. Medicare has proposed major changes to Medicare Part B in an attempt to slow the explosion in healthcare expenditures. In addition, a recent “report” by a group called…
What is Value for Patients in the Management of Prostate Cancer.
At all stages of and levels of prostate cancer, whether you have low, intermediate, or high risk disease, whether you are newly diagnosed, have recurrent disease or your prostate cancer has advanced and metastasized, the same questions arise. What is…
Preventing Relapse in Multiple Myeloma
Recent introduction of new therapies has significantly improved outcomes for patients diagnosed with multiple myeloma. However, cures remain rare in myeloma and most people may eventually relapse. If we can better understand how and why myeloma grows back, there is…